Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Wikidata - wikimedia - TriplyDB

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

http://www.wikidata.org/entity/Q24289281

about

Developing Global Norms for Sharing Data and Results during Public Health Emergencies The 2014–2015 Ebola outbreak in West Africa: Hands On A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report Ebola virus disease and critical illness.Clinical development of Ebola vaccines Filoviruses: One of These Things is (not) Like the Other Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?[Back to the Future. Vaccine trials against Ebola in the history of resistance to immunization].Insights from clinical research completed during the west Africa Ebola virus disease epidemic.A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus Monoclonal antibodies for the treatment of Ebola virus disease.Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection.Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa.Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub Ebola vaccine R&D: Filling the knowledge gaps.Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.Closer than ever to an Ebola virus vaccine.In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings.Fighting Ebola: A Window for Vaccine Re-evaluation?Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays

P2860

Q23331292-25188A74-D9DD-4D58-85D1-D1EFEBED1B2C Q24049114-72A6D8F9-A337-429B-B9E3-B2D29A939B6C Q24289279-DD15E7B7-AE6F-4F64-87E9-F5F1BD73D728 Q24289295-9D8E7408-35E3-4187-9691-4081EF61DD98 Q26250274-1D561A47-0E71-4642-8113-85648B1946D1 Q26775792-291FBD61-D238-425F-A68A-26C995035227 Q26783063-094ED70A-7853-46BF-B38B-9ABA302642FB Q28051937-BEE97BEE-1274-4030-86C5-5A2FD727C01A Q28397866-CD9240F9-39E7-4C37-B4ED-801596762AAE Q29048611-86EC6ACA-D38C-4340-84B7-07A2A18C9D14 Q29994671-C2E0DBDE-B7FC-4039-BEBB-23CDCDFC2A2B Q30151742-7CDF0033-DC79-4CEB-83C0-8858FFD5ADBD Q30234590-7DEE73A6-88D0-41C6-8DF4-E4262AE5E1BA Q30235073-61374B1F-16C0-473D-8788-037F1BE24EF6 Q30245073-0F57C0C3-A952-4724-984A-F1B0EEB2380B Q33681247-A6365436-B9D6-4950-B49F-E8276D7C799A Q33715773-5FD23B5E-ACA6-4756-82C6-69A0D0D453F2 Q33818337-752EC1B8-7304-4B72-9451-174AE15401D7 Q33837161-5B4FFED6-214F-4379-95DC-5927FFE162DB Q33924959-F2BCFE9B-8264-4632-B4D6-8517920F3759 Q34500955-11B5C3D6-7193-472C-9292-68DB79907B7A Q34504883-CE404FB8-7366-4EAE-A8ED-B9E096CA2677 Q34531417-F07DA9A3-4FD5-473C-A748-BD39436B3F25 Q34540207-FB0D9E12-082B-41DA-AE75-A02272DA4A6E Q34553720-C57968C3-AAEA-4A1F-8DCD-A4465B20B5F2 Q35689217-D4297498-9C75-4BD9-8881-C0563853418C Q35847032-9000C0E8-E26D-4BF1-9D16-39747079CFBC Q35858437-1C261459-5D9B-46C5-8A26-B7FF13392FBD Q36043269-C86AE4A3-32E9-4E8F-BDB3-A00F9EDFD7CB Q36043284-50D4BDCB-1963-42A6-B442-DD8CF407F8EE Q36107075-9C0308A5-8C01-4C27-AEAA-9D7542DC796A Q36247762-1481A3B0-301C-41A5-B9FF-62539702B288 Q36300818-FA38D44F-7DCF-4C84-967F-8ABF43585F2C Q36382902-4C25CE84-378E-4E7A-9480-4FF6D2037373 Q36403500-FAD3578D-E9EA-42F6-88AA-3EDC73E747E1 Q36499251-3B0F4403-D73F-4343-BCA1-89DBB47378D5 Q36538834-A6AFF838-0772-4FD1-99D3-F35FA78F3739 Q36580268-42D5A64C-E974-4C59-BC35-9519E39647CD Q36654562-514AC8D3-C332-4241-94D7-CC9D42FC4050 Q36748120-197CAC6D-00FF-4548-956E-D78A05B194EB

P2860

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

http://www.wikidata.org/entity/Q24289281

description

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@ast

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en-gb

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@nl

type

label

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@ast

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en-gb

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@nl

prefLabel

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@ast

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en-gb

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@nl

P1433

Q24289281-0F2DAA39-34B8-4352-B1BE-2B553055861D

P1476

Q24289281-E2F82237-3F28-4892-BBAC-7D945E656990

P2093

Q24289281-02387074-BACD-45AB-98E9-53BBE2C1B1C8

Q24289281-0730E115-C5DA-40EE-941C-B717E9949523

Q24289281-0E28114D-1EFE-42FC-8C96-1EC3D530CC68

Q24289281-0F20E472-BD8A-4283-8F01-8E19C390704E

Q24289281-232B179A-0E09-42B4-BC41-D67593DCC522

Q24289281-3578F89F-4587-4B5E-8962-B14ABC07B059

Q24289281-4215EF0E-F778-4623-A799-3FE6A78A7794

Q24289281-48467B49-DAF3-40F5-903B-5ACEC0794FB1

Q24289281-494C1D25-F7C6-48D7-81B2-15F0BF03D726

Q24289281-4BEB5264-5622-45FC-B5AE-53C456419C69

P2860

Q24289281-00583A1B-F136-424C-B84D-0C2167AA93E5

Q24289281-12970511-FFDF-4092-AE04-01030C578979

Q24289281-183FA3CD-61F1-416C-9460-7C49F17A308A

Q24289281-1A1B687E-BEE6-44C9-9A47-9A243EEF4267

Q24289281-3593FF61-5AE0-45A0-BF75-9BEF9DDA9E0C

Q24289281-3EE03228-BE7E-41EB-B939-0813BD8E7C29

Q24289281-439B3DE2-E894-4608-86E0-299935406BE4

Q24289281-4455D832-A4C8-41C5-868D-91BA9A5E22E3

Q24289281-53FBB0D5-D081-45D3-A486-65929D74E74E

Q24289281-5D168AEB-E304-4EF4-A3DE-A8D0DD163DD7

P304

Q24289281-2F480999-F9B2-46BC-8773-2ACBFBB24B81

P31

Q24289281-3D037EC8-92C9-451C-8C71-C0FDBC29E91C

P3181

Q24289281-EE00C476-3726-4232-A747-907F03D52C45

P356

Q24289281-360F20C4-117F-4CC6-B4E8-D2939AE60F4C

P407

Q24289281-7D0271EF-BAD1-412C-962D-642B7E163C31

P433

Q24289281-0D555A65-E8AF-4BDE-9EF4-6AE1DD728E26

P478

Q24289281-D1503998-5A94-4D92-8BAC-AF415142BDF3

P50

Q24289281-01151477-5817-41AA-BD0D-B3D898F68218

Q24289281-01D5FC56-489F-4B08-90CA-79C40A64ADE6

Q24289281-2A87755B-C0A3-4F05-8193-6FCDAA2369F8

Q24289281-36062966-1CD3-479F-9565-72ED7C3B3A57

Q24289281-3918A8C3-C700-4767-B923-D801E09C6047

Q24289281-54D1104E-8712-4E0B-84EC-785C62F73491

Q24289281-5EDB6895-5465-4E68-95F1-18F14B0E263E

Q24289281-81006E4C-2BA4-42EC-9C8A-A4CE64FFB19C

Q24289281-9EE2F83F-4AE6-486E-B1FF-9BE9CED0C143

Q24289281-B1A35655-0EB8-4563-B928-E71FF978B515

P577

Q24289281-F516F0DA-0351-41B2-9E7B-1A67B962AE3E

P5875

Q24289281-935791D5-3FF9-4339-AFB9-15F15A10A3F4

P698

Q24289281-48B9131A-5413-4603-A552-18F090CDA65C

P921

Q24289281-0299820C-E245-4B71-BF21-46D9A2924356

Q24289281-41154195-6A65-4580-9AD8-61231E0C4CB9

Q24289281-83CD903B-C668-4B19-B2A2-626B85197F53

P932

Q24289281-0C54BB04-3857-4AC3-B781-207A2B6D0339

P3181

P356

P1433

The New England Journal of Medicine

P1476

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

@en

P2093

Akim A Adegnika

http://www.w3.org/2001/XMLSchema#string

Alain Matthey

http://www.w3.org/2001/XMLSchema#string

Alen Jambrecina

http://www.w3.org/2001/XMLSchema#string

Ana Rita Goncalves

http://www.w3.org/2001/XMLSchema#string

Angela Huttner

http://www.w3.org/2001/XMLSchema#string

Anita L Kabwende

http://www.w3.org/2001/XMLSchema#string

Anne Nolting

http://www.w3.org/2001/XMLSchema#string

Ansgar W Lohse

http://www.w3.org/2001/XMLSchema#string

Axel Finckh

http://www.w3.org/2001/XMLSchema#string

Barbara Lemaître

http://www.w3.org/2001/XMLSchema#string

P2860

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses

Functional role of type I and type II interferons in antiviral defense

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

Attenuated vesicular stomatitis viruses as vaccine vectors

Understanding and altering cell tropism of vesicular stomatitis virus

Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease

2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States.

RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis.

Vesicular stomatitis.

P304

1647-1660

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

611354

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1502924

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Martin Peter Grobusch

Michael Ramharter

Peter Gottfried Kremsner

Benjamin Mordmüller

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274401111

http://www.w3.org/2001/XMLSchema#string

P698

25830326

http://www.w3.org/2001/XMLSchema#string

P921

Vaccine against Ebola

phase I clinical trial

P932

5490784

http://www.w3.org/2001/XMLSchema#string